These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9516860)

  • 1. The current contribution of molecular factors to risk estimation in neuroblastoma patients.
    Berthold F; Sahin K; Hero B; Christiansen H; Gehring M; Harms D; Horz S; Lampert F; Schwab M; Terpe J
    Eur J Cancer; 1997 Oct; 33(12):2092-7. PubMed ID: 9516860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
    Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
    Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
    Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
    Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
    Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
    Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
    Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
    Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
    Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
    Lastowska M; Cullinane C; Variend S; Cotterill S; Bown N; O'Neill S; Mazzocco K; Roberts P; Nicholson J; Ellershaw C; Pearson AD; Jackson MS;
    J Clin Oncol; 2001 Jun; 19(12):3080-90. PubMed ID: 11408505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.